Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 6Lung Neoplasms 2Neoplasms 1Leiomyosarcoma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 29pembrolizumab 25Pemetrexed 25Specimen Handling 22Cisplatin 20Magnetic Resonance Spectroscopy 18Paclitaxel 15Gemcitabine 13Docetaxel 12durvalumab 9Nivolumab 8osimertinib 7Taxes 7Immunoglobulin G 7Disulfides 7130-nm albumin-bound paclitaxel 7atezolizumab 6Etoposide 6Platinum 5Cetuximab 51,2-diaminocyclohexaneplatinum II citrate 5X-Rays 4Ramucirumab 4Radiotherapy 4Radiation 4Observation 4Interviews as Topic 4Biopsy 4Albumin-Bound Paclitaxel 4patritumab deruxtecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × PM 01183 × 30 days × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT05800587 2026-05-22

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2 Recruiting
280 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡